Posted by Michael Wonder on 31 Aug 2020
ICER to assess CAR-T cell therapies for multiple myeloma
31 August 2020 - Report will be subject of Midwest CEPAC meeting in April 2021; open input now being accepted until 17 September 2020.
The Institute for Clinical and Economic Review announced today that it plans to assess the comparative clinical effectiveness and value of idecabtagene vicleucel (Bristol-Myers Squibb, bluebird bio) and ciltacabtagene autoleucel (Johnson & Johnson, Legend Biotech) for the treatment of multiple myeloma.
An FDA decision on idecabtagene vicleucel is expected in early 2021. A BLA submission for ciltacabtagene autoleucel is expected by end of 2020.
